{"url_path":"/sec/inkt/8-k/2026-06-23/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1840229/0001193125-26-278642-index.html","accession_number":"0001193125-26-278642","cik":"0001840229","ticker":"INKT","issuer_name":"MiNK Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1840229/0001193125-26-278642-index.html","primary_entity_key":"0001840229","primary_entity_name":"MiNK Therapeutics, Inc."},"word_count":283,"has_tables":true,"body_markdown":"## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\n \n\nThe Company held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 17, 2026. A total of 3,277,906 shares of common stock, representing 65.79% of the shares outstanding and eligible to vote and constituting a quorum, were present at the Annual Meeting or represented by valid proxies. At the Annual Meeting, the Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 23, 2026: (i) to elect Garo Armen, Barbara Ryan and John Holcomb as Class II Directors, each for a term of three years expiring at the 2029 Annual Meeting of Stockholders (“Proposal 1”), (ii) to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 2”).\n\nThe Company’s stockholders elected each of the Class II Director nominees nominated for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for the Class II Directors as follow:\n\nClass II Director Nominees\n\nFor\n\nAgainst\n\nWithheld\n\nBroker Non-Votes\n\nGaro Armen\n\n2,363,360\n\n0\n\n32,898\n\n881,648\n\nBarbara Ryan\n\n2,362,760\n\n0\n\n33,498\n\n881,648\n\nJohn Holcomb\n\n2,381,491\n\n0\n\n14,767\n\n881,648\n\nThe Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows:\n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n3,249,124\n\n26,560\n\n2,222\n\n0\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDate:\n\nJune 23, 2026\n\nBy:\n\n/s/ Jennifer S. Buell, Ph.D.\n\n \n\n \n\n \n\nJennifer S. Buell, Ph.D.\nPresident and CEO"}